Kura Oncology Shares Surge Following Positive Kidney Cancer Trial Data [TheStreet.com]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: TheStreet.com
Investors reacted strongly after the company released promising preliminary data from a recent kidney cancer clinical trial. The trial, known as FIT-001, tested a new drug combination on patients with clear cell renal cell carcinoma (ccRCC). Specifically, researchers evaluated how darlifarnib works alongside cabozantinib. The results highlight significant progress for patients who previously received cabozantinib treatments. Overall, the data paints an encouraging picture. The combination therapy achieved a 44% objective response rate and an impressive 94% disease control rate. Furthermore, doctors observed tumor shrinkage in 75% of the treated patients. Looking closer at the study, the analysis focused on a subset of 16 ccRCC patients. All participants had previously undergone immunotherapy and cabozantinib treatments. Their time on the new therapy ranged from 8 to 56 weeks. At the time researchers gathered the data, six patients still remained on the treatment. Notably, even h
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript [Seeking Alpha]Seeking Alpha
- Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswire
- Kura Oncology (KURA) was upgraded by Lake Street Capital to "strong-buy".MarketBeat
- Kura Oncology (KURA) is now covered by Lake Street Capital. They set a "buy" rating on the stock.MarketBeat
- Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 [Yahoo! Finance]Yahoo! Finance
KURA
Earnings
- 3/5/26 - Miss
KURA
Sec Filings
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- 4/10/26 - Form DEF
- KURA's page on the SEC website